Cited by 144Monoclonal and Polyclonal Antibodies ResearchBiosimilars and Bioanalytical MethodsPharmaceutical studies and practices

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

Ling, Jie, Zhou, Honghui, Jiao, Qun, Davis, Hugh M.·2009·The Journal of Clinical Pharmacology

DOI 10.1177/0091270009337134

Open this paper in CoChat — free account

Abstract

The authors evaluated interspecies scaling for the prediction of human clearance of 18 therapeutic monoclonal antibodies (mAbs). Human and monkey/chimpanzee data of 14 mAbs were classified based on the targeted antigens (soluble or membrane bound). Simple allometry and/or a time‐invariant method (elementary Dedrick plot) were performed. Results indicate that human clearance might be accurately predicted from monkey data for mAbs targeting soluble receptors or membrane‐bound receptors with limited tissue distribution using simplified allometry. The optimal exponents were estimated to be 0.85 or 0.90. If nonlinearity is anticipated at the human efficacious dose, pharmacokinetic parameters obtained at high doses in animals might not be sufficient for full pharmacokinetic characterization and prediction. Using prespecified criteria, including predicted human clearance (≤ or > 10 mL/d/kg), simplified allometric scaling might be helpful in predicting the effect of receptor‐mediated clearance for mAbs targeting membrane‐bound antigens. Furthermore, simplified allometry and an elementary Dedrick plot provide similar results in predicted clearance. Given the significant advantages offered by simplified allometry, it should be used when data are available from only 1 species. When reasonable data from ≥3 species are available, traditional allometry should be explored. Overall, clearance prediction is useful for human dose prediction in drug discovery and development.

Integrity signals

Registry

Crossref · 10.1177/0091270009337134

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N. M., Guzzo, C. A., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,870
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Papp, K. A., Langley, R. G. B., Lebwohl, M., Krueger, G. G., Szapary, P. O., Yeilding, N. M., Guzzo, C. A., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,358
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
Gordon, M. S., Margolin, K. A., Talpaz, M., Sledge, G. W., Holmgren, E. B., Benjamin, R. S., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 741
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall’Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 648
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 2×
“Although successful prediction using a single species or a fixed exponent has been published,(30,51,55,66) the general consensus has been that 3 or 4 species are required for human CL prediction.(14,15,28,32) It has been previously demonstrated that CL for 3 mAbs (pertuzumab, bevacizumab, and trastuzumab) could be acc…”
Background
Scaling: Why is Animal Size so Important?
Mace, G. M. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90197-3 · Cited by 641
Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies
Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502
Quantitative Relations in the Physiological Constitutions of Mammals
Adolph, E. F. (1949) · Science · doi:10.1126/science.109.2841.579 · Cited by 497
Elimination mechanisms of therapeutic monoclonal antibodies
Tabrizi, M. A., Tseng, C.-M. L., & Roskos, L. K. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03638-x · Cited by 479
Rituximab
Plosker, G. L., & Figgitt, D. P. (2003) · Drugs · doi:10.2165/00003495-200363080-00005 · Cited by 471
A Theoretical Model of γ-Globulin Catabolism
Brambell, F. W. R., Hemmings, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 461
Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Man versus Beast: Pharmacokinetic Scaling in Mammals
Mordenti, J. J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 387
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
Lü, J., Bruno, R., Eppler, S., Novotny, W. F., Lum, B. L., & Gaudreault, J. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0664-8 · Cited by 364
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice
Garg, A., & Balthasar, J. P. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9065-1 · Cited by 329
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
Rowinsky, E. K., Schwartz, G. H., Gollob, J., Thompson, J. A., Vogelzang, N. J., Figlin, R. A., Bukowski, R. M., Haas, N. B., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
Adams, C. W., Allison, D. E., Flagella, K. M., Presta, L. G., Clarke, J. B., Dybdal, N. O., McKeever, K., & Sliwkowski, M. X. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 280
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. G. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 270
Bioenergetics and Growth
(1979) · Fish physiology · doi:10.1016/s1546-5098(08)x6002-9 · Cited by 269
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor
Lin, Y. S., Nguyen, C. B., Mendoza, J.-L., Escandón, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 256
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
Bruno, R., Washington, C. B., Lü, J., Liebérman, G., Banken, L., & Klein, P. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1026-z · Cited by 248
Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial
Ng, C. M., Bruno, R., Combs, D., & Davies, B. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005277075 · Cited by 203
Interspecies correlation of plasma concentration history of methotrexate (NSC-740).
Dedrick, R. L., Bischoff, K. B., & Zaharko, D. S. (1970) · PubMed · Cited by 184
Similarity and Dimensional Methods in Biology
Stahl, W. R. (1962) · Science · doi:10.1126/science.137.3525.205 · Cited by 177
Metabolic turnover rate: A physiological meaning of the metabolic rate per unit body weight
Kleiber, M. (1975) · Journal of Theoretical Biology · doi:10.1016/0022-5193(75)90110-1 · Cited by 158
A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Fracasso, P. M., Burris, H. A., Arquette, M. A., Govindan, R., Gao, F., Wright, L. P., Goodner, S. A., Greco, F. A., Jones, S. F., Willcutt, N. T., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1542 · Cited by 153
Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins
Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B., & Green, J. D. (1991) · Pharmaceutical Research · doi:10.1023/a:1015836720294 · Cited by 152
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
Mahmood, I., & Green, M. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00001 · Cited by 150 · cited 1×
“In addition, the patient population, concomitant medication use, and immunogenicity might also affect the CL of a mAb.(3,19) According to Tabrizi et al,(19) mAbs can be classified into 2 categories: those that target soluble antigens and those that target membrane-bound antigens.”
Background
Allometric Scaling of Pharmacokinetic Parameters in Drug Discovery: Can Human CL, Vss and T1/2 Be Predicted Fromin-Vivo Rat Data?
Caldwell, G. W., Masucci, J. A., Yan, Z., & Hageman, W. (2004) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190588 · Cited by 148
Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors
Mullamitha, S., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K. E., Cheung, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2779 · Cited by 146
Self-citation
Interspecies pharmacokinetic scaling and the Dedrick plots
Boxenbaum, H. G., & Ronfeld, R. A. (1983) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1983.245.6.r768 · Cited by 146
A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141
Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates
Datta‐Mannan, A., Witcher, D. R., Tang, Y., Watkins, J. D., Jiang, W., & Wroblewski, V. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.011734 · Cited by 136
Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis
Bauer, R. J., Dedrick, R. L., White, M., Murray, M. J., & Garovoy, M. R. (1999) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1023/a:1020917122093 · Cited by 135
Estimating the starting dose for entry into humans: principles and practice
Reigner, B. G., & Blesch, K. S. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0405-6 · Cited by 132
Panitumumab the first fully human monoclonal antibody: from the bench to the clinic
Cohenuram, M. K., & Saif, M. W. (2006) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32800feecb · Cited by 130
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
Sheremata, W. A., Vollmer, T. R., Stone, L. A., Willmer–Hulme, A., & Köller, M. (1999) · Neurology · doi:10.1212/wnl.52.5.1072 · Cited by 128
Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
Tokuda, Y., Watanabe, T., Omuro, Y., Ando, M., Katsumata, N., Okumura, A., Ohta, M., Fujii, H., Sasaki, Y., Niwa, T., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690343 · Cited by 114
Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
Xu, Z., Seitz, K., Fasanmade, A. A., Ford, J. A., Williamson, P., Xu, W., Davis, H. M., & Zhou, H. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008316886 · Cited by 109
Self-citation
A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs
Davda, J. P., Jain, M., Batra, S. K., Gwilt, P. R., & Robinson, D. H. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.10.023 · Cited by 107
The clinical pharmacology of therapeutic monoclonal antibodies
Roskos, L. K., Davis, C., & Schwab, G. M. (2004) · Drug Development Research · doi:10.1002/ddr.10346 · Cited by 102
A Comprehensive Analysis of the Role of Correction Factors in the Allometric Predictivity of Clearance from Rat, Dog, and Monkey to Humans
Nagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to Humans
Mahmood, I. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10531 · Cited by 91
Scaling basic toxicokinetic parameters from rat to man.
Bachmann, K., Pardoe, D., & White, D. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104400 · Cited by 90
Interspecies scaling of renally secreted drugs
Mahmood, I. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00525-6 · Cited by 88
Interspecies scaling: A comparative study for the prediction of clearance and volume using two or more than two species
Mahmood, I., & Balian, J. D. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00339-6 · Cited by 72
Fc receptors and the action of antibodies
(1991) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(91)90035-5 · Cited by 67
Allometric Pharmacokinetic Scaling: Towards the Prediction of Human Oral Pharmacokinetics
Feng, M. R., Lou, X., Brown, R. R., & Hutchaleelaha, A. (2000) · Pharmaceutical Research · doi:10.1023/a:1007520818956 · Cited by 63
Correlation of Plasma Clearance of 54 Extensively Metabolized Drugs Between Humans and Rats: Mean Allometric Coefficient of 0.66
Chiou, W. L., Robbie, G. J., Chung, S. M., Wu, T., & Ma, C. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974226596 · Cited by 61
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates
Kelley, S. K., Gelzleichter, T. R., Xie, D., Lee, W. P., Darbonne, W. C., Qureshi, F., Kissler, K. M., Oflazoglu, E., & Grewal, I. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706828 · Cited by 59
Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates
Kelley, S. K., Gelzleichter, T. R., Xie, D., Lee, W. P., Darbonne, W. C., Qureshi, F., Kissler, K. M., Oflazoglu, E., & Grewal, I. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707129 · Cited by 58
Clearance of Fentanyl, Alfentanil, Methohexitone, Thiopentone and Ketamine in Relation to Estimated Hepatic Blood Flow in Several Animal Species: Application to Prediction of Clearance in Man
Björkman, S. E., & Redke, F. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001774985 · Cited by 52
Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding
Martin, P. L., Jiao, Q., Cornacoff, J. B., Hall, W. C., Saville, B. A., Nemeth, J. A., Schantz, A., Mata, M., Jang, H., Fasanmade, A. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2623 · Cited by 42
Self-citation
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms
Vugmeyster, Y., Szklut, P., Tchistiakova, L., Abraham, W. M., Kasaian, M. T., & Xu, X. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2007.12.004 · Cited by 40
Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu corrected intercept method’ (FCIM)
Mahmood, I. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20650 · Cited by 34
A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods
Mahmood, I., & Yuan, R. (1999) · Biopharmaceutics & Drug Disposition · doi:10.1002/(sici)1099-081x(199904)20:3 · Cited by 34
Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species
Boxenbaum, H., & Fertig, J. (1984) · European journal of drug metabolism and pharmacokinetics · doi:10.1007/bf03189622 · Cited by 28
The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2
Eugster (1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1521-4141(199807)28:07 · Cited by 2
A population pharmacokinetic (PK) analysis of ABX-IL8, a fully human monoclononal IGG antibody, in psoriasis patients
WANG, B., Roskos, L., Osborn, K. G., Lu, H., Kim, M. L. L., Pasumarthi, R., RAIE, N., & TABRIZI, M. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.12.240 · Cited by 2

Research works printed but not linked: 22

Food and Drug Administration (FDA)., 2002, Guidance for Industry: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers
Teorell T., 1937, Kinetics of distribution of substances administered to the body, Arch Intern Pharmacodyn, 57, 205
Mahmood I., 2004, Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, 423
Tysabri (natalizumab) pharmacology review.www.fda.govcderfoinda2004125104s000Natalizumab.htm.
Raptiva (efalizumab) pharmacology review.http:www.fda.govcderfoinda20031250750000RaptivaPharmrP1.pdf.
2005, Zenapax [package insert]
2008, Raptiva [package insert]
2008, Remicade [package insert]
2008, Erbitux [package insert]
2008, Avastin [package insert]
2008, Herceptin [package insert]
2008, Vectabix [package insert]
2008, Tysabri [package insert]
Erbitux (cetuximab) pharmacology review.http:www.fda.govcderbiologicsnda125084ERBITUXBIOPHARMR.PDF.
Zenapax (daclizumab) nonclinical pharmacology and toxicology review.http:www.fda.govcderbiologicsreviewdaclhof121097r2.pdf.
Gabrielsson J, 2000, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts & Applications
DengR MortensenD PrabhuS et al.Prediction of human pharmacokinetics for monoclonal antibody. Presented at: AAPS National Biotechnology Conference;June 2427 2007; San Diego CA.
2008, Rituxan [package insert]
Vozeh S, 1989, Pharmacokinetic Drug Data: Clinical Pharmacokinetic Drug Data Handbook
Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling
2009, Simponi [package insert]
Herceptin (trastuzumab) clinical pharmacology review.http:www.fda.govcderbiologicsreviewtrasgen092598r3.pdf.

Sorted by citations

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 407
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Dostálek, M., Gardner, I. B., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 236
Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
Wang, W., Lü, P., Fang, Y., Hamuro, L., Pittman, T. J., Carr, B. I., Hochman, J. H., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 171

See all 144

Authors: Ling, J., Zhou, H., Jiao, Q., & Davis, H. M.
Corresponding author: Ling, Jie
ORCID: Ling, Jie
Zhou, Honghui
Venue: The Journal of Clinical Pharmacology
Publisher: Wiley
Published: 2009-12
Volume: 49
Issue: 12
Pages: 1382-1402
ISSN: 0021-9754 (ISSN-L)
0091-2700
1552-4604
DOI: 10.1177/0091270009337134
OpenAlex: W2011077241
Cited by: 144
References: 68
Citations by year: 2026: 4 · 2025: 4 · 2024: 15 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 6 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 10 · 2015: 14 · 2014: 11 · 2013: 11 · 2012: 10
FWCI: 1.15
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 1192 d)
Locations: The Journal of Clinical Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords: interspecies scaling, therapeutic monoclonal antibodies, soluble receptor, cell surface receptors, receptor-mediated clearance
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Metabolic Clearance Rate, Species Specificity, Models, Animal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks